Biohaven Pharmaceutical Holding Company Ltd.
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.72 USD | -2.25% | -12.06% | -74.49% |
Apr. 23 | Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO | MT |
Apr. 23 | UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-74.49% | 541M | |
+4.09% | 43.84B | |
+46.96% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- BHVN Stock
- News Biohaven Pharmaceutical Holding Company Ltd.
- Biohaven Pharmaceutical's Proposed ALS Treatment Fails to Meet Primary, Secondary Targets in Phase 2/3 Trial